Characteristics of second primary lung malignancy in patients with known breast cancer

Southern Medical Journal

Volumn 102, Issue 3, 2009, Pages 269-274

  Kerendi, Faraz ^a   Gal, Anthony ^a   Corvera, Joel S ^a   Halkos, Michael E ^a   Miller, Joseph I ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOT   (United States)

Author keywords

Breast cancer; Lung cancer; Lung resection

Indexed keywords

TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG CANCER; PARTIAL MASTECTOMY; SECOND CANCER; SMOKING CESSATION; ADENOCARCINOMA; AGED; BREAST TUMOR; CANCER DIAGNOSIS; COHORT ANALYSIS; KAPLAN MEIER METHOD; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; AGED; BREAST NEOPLASMS; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; EARLY DETECTION OF CANCER; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK;

EID: 63149097905     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e318197fec6     Document Type: Article

References (24)

1. La Francis IE, Cooper RB. Second primary malignancies associated with primary female breast cancer: a review of the Danbury Hospital experience. Conn Med 1992;56:411-414.
2. Robinson E, Adler Z, Nasrallah S, et al. Clinical characteristics of second primary tumors following breast cancer. Isr J Med Sci 1995;31: 169-171.
3. Lee YT. Additional malignant neoplasms in patients with breast carcinoma. J Surg Oncol 1986;31:199-203. (Pubitemid 16133599)
4. Volk N, Pompe-Kirn V. Second primary cancers in breast cancer patients in Slovenia. Cancer Causes Control 1997;8:764-770. (Pubitemid 27404647)
5. Buiatti E, Crocetti E, Acciai S, et al. Incidence of second primary cancers in three Italian population-based cancer registries. Eur J Cancer 1997;33:1829-1834. (Pubitemid 28129212)
6. Okamoto N, Morio S, Inoue R, et al. The risk of a second primary cancer occurring in five-year survivors of an initial cancer. Jpn J Clin Oncol 1987;17:205-213.
7. Andersson M, Jensen MB, Engholm G, et al. Risk of second primary cancer among patients with early operable breast cancer registered or randomised in Danish Breast Cancer cooperative Group (DBCG) protocols of the 77, 82 and 89 programmes during 1977-2001. Acta Oncol 2008;47:755-764. (Pubitemid 351878439)
8. Kirova YM, De Rycke Y, Gambotti L, et al. Institut Curie Breast Cancer Study Group. Second malignancies after breast cancer: the impact of different treatment modalities. Br J Cancer 2008;98:870-874.
9. Raymond JS, Hogue CJ. Multiple primary tumours in women following breast cancer, 1973-2000. Br J Cancer 2006;94:1745-1750.
10. Matesich SM, Shapiro CL. Second cancers after breast cancer treatment. Semin Oncol 2003;30:740-748. (Pubitemid 38010128)
11. Galper S, Gelman R, Recht A, et al. Second nonbreast malignancies after conservative surgery and radiation therapy for early-stage breast cancer. Int J Radiat Oncol Biol Phys 2002;52:406-414. (Pubitemid 34173002)
12. Grenader T, Goldberg A, Shavit L. Second cancers in patients with male breast cancer: a literature review. J Cancer Surviv 2008;2:73-78.
13. Suster S, Moran CA. Unusual manifestations of metastatic tumors to the lungs. Semin Diagn Pathol 1995;12:193-206.
14. Kanashiki M, Satoh H, Ishikawa H, et al. Outcome of patients with lung cancer detected incidentally. Oncol Rep 2004;12:945-948.
15. Kaufmann O, Deidesheimer T, Muehlenberg M, et al. Immunohistochemical differentiation of metastatic breast carcinomas from metastatic adenocarcinomas of other common primary sites. Histopathology 1996;29:233-240. (Pubitemid 26302731)
16. Raab SS, Berg LC, Swanson PE, et al. Adenocarcinoma in the lung in patients with breast cancer. A prospective analysis of the discriminatory value of immunohistology. Am J Clin Pathol 1993;100:27-35.
17. Bejarano PA, Baughman RP, Biddinger PW, et al. Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas. Mod Pathol 1996;9:445-452.
18. Khoor A, Whitsett JA, Stahlman MT, et al. Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma. Hum Pathol 1999;30:695-700. (Pubitemid 29266730)
19. Bohinski RJ, Bejarano PA, Balko G, et al. Determination of lung as the primary site of cerebral metastatic adenocarcinomas using monoclonal antibody to thyroid transcription factor-1. J Neurooncol 1998;40:227-231. (Pubitemid 29054658)
20. Ludwig C, Stoelben E, Hasse J. Disease-free survival after resection of lung metastases in patients with breast cancer. Eur J Surg Oncol 2003;29:532-535. (Pubitemid 37009971)
21. Friedel G, Pastorino U, Ginsberg RJ, et al. International Registry of Lung Metastases, London, England. Results of lung metastasectomy from breast cancer: prognostic criteria on the basis of 467 cases of the International Registry of Lung Metastases. Eur J Cardiothorac Surg 2002;22:335-344.
22. Hurria A, Leung D, Trainor K, et al. Screening chest imaging studies are not effective in the follow-up of breast cancer patients. J Oncol Manag 2003;12:13-15.
23. Cahan WG, Castro EB. Significance of a solitary lung shadow in patients with breast cancer. Ann Surg 1975;181:137-143.
24. Casey JJ, Stempel BG, Scanlon EF, et al. The solitary pulmonary nodule in the patient with breast cancer. Surgery 1984;96:801-805. (Pubitemid 14019729)